Lovenox news from FierceBiotech
NewsBayer, J&J tout rivaroxaban data
In a head-to-head study against Sanofi's Lovenox, Bayer and J&J's oral anti-clotting drug rivaroxaban proved superior in preventing venous blood clots in patients who underwent total knee Read more...
ALSO NOTED: AIDS vaccine researchers years away from success; Amgen reports earnings; and much more...
> Following a series of major setbacks trying to develop a vaccine for AIDS, pessimistic researchers say they're years away from success. Read more...
Boehringer wins approval in anti-clotting drug race
Boehringer Ingelheim has stolen a march on arch rival Bayer, winning European marketing approval for a new anti-clotting agent--Read more...
FDA rejection raises serious questions for Momenta
The fallout over the FDA's rejection of Momenta's generic version of Lovenox--a rare setback for Read more...
Momenta shares tumble after FDA rejection
It's Momenta Pharmaceuticals' turn at the Wall Street whipping post as investors respond to the news that the FDA has rejected its Read more...
| Press ReleasesPRESS RELEASE: Momenta Pharmaceuticals Says U.S. FDA Rejects its Generic Lovenox Momenta Pharmaceuticals Says U.S. FDA Rejects its Generic Lovenox CAMBRIDGE, Mass., Nov. 6, 2007 -- Momenta Pharmaceuticals, Inc. (NasdaqGM:MNTA - News) today announced that its collaboration Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets